Breaking News

The White House's phantom pandemic office, a new MA crackdown, and user fee revivals

April 6, 2023
Reporter, D.C. Diagnosis Writer
Good morning, and happy Thursday! We're opening up applications for an inspiring STAT program that recognizes the best and brightest early-career researchers — and that includes health policy researchers, too, like last year's honoree, Hussain Lalani of Harvard's PORTAL center. Nominate an outstanding young person in your life here, and reach out to me with news anytime at rachel.cohrs@statnews.com.
Biden administration

The White House's phantom pandemic office

Congress in December created a new pandemic response office at the White House so that the government doesn't have to frantically search for a czar every time the country faces a public health crisis. 

The problem? The White House hasn't gotten around to creating the new office, or even appointing someone to lead it, just a month before the public health emergency ends. White House Covid-19 Response Coordinator Ashish Jha has been publicly saying that it's time for the emergency phase of the pandemic response to end.

But it's unclear what the post-emergency infrastructure will look like. Experts told STAT that the closer the election gets, the harder it will be to stand an office up. Read more in my story out this morning, including a comment from one key lawmaker who is watching the process with great interest. 


regulation watch

The Biden administration cracks down on Medicare Advantage denials

The Biden administration is moving forward with proposals that would crack down on Medicare Advantage insurers that deny care inappropriately, my colleague Bob Herman reports.

The rule means that if traditional Medicare has to cover a procedure, drug, test or supply, Medicare Advantage plans have to cover it, too. 

The federal government also specifically called out the use of algorithms being used to reject care. A recent STAT investigation by Bob and Casey Ross found Medicare Advantage companies increasingly have used unregulated algorithms to determine when they can cut off patients' care. Read more.


congress

User fee leftovers on the menu

The buzz on K Street this week is that the Senate could warm up some leftovers from last year's bipartisan user fee package, in a modest new effort that looks likely to include some bipartisan health care policy.

I needed a refresher on some of the Senate user fee policies from last May that didn't make the final cut, so I sorted through all the documentation — and I thought I'd share my work here to make your life easier. 

The buzziest unresolved items would give the government authority to regulate diagnostic tests developed in clinical labs (e.g. Theranos), empower the FDA to regulate dietary supplements, and require the FDA to issue regulations allowing drug importation from Canada. Have any ideas on what might actually make it in? Drop me a line



covid-19

A year of Biden's long Covid plan

It's been a year since President Biden called for a whole-of-government response to long Covid, and HHS on Wednesday touted its progress so far. Items that made the list included:

  • The Veterans Affairs administration has 23 clinical facilities with long Covid programs
  • HHS writ large has held 11 telehealth training sessions for primary care providers in rural areas
  • It also produced a 124-page document listing resources for patients with long Covid
  • The Social Security Administration is funding research into long Covid's effect on the workforce
  • HHS has published analyses based on data from electronic health records

However, the list leaves some high-profile items undone from the agency's plan, too. For example, in the same vein as my first item in this newsletter, the agency hasn't stood up a HHS Office of Long Covid Research and Practice, which it promised to do in August. Planned clinical trials of therapeutics outlined in the document haven't started. And ARPA-H hasn't begun to name its priority disease areas yet, and whether long Covid could be on the list.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Research misconduct allegations put Stanford's president — and science — under an uncomfortable spotlight, STAT
  • When my husband was finally diagnosed with dementia, I vowed to take care of him. Then he filed for divorce, The Cut
  • FTC tells Illumina to divest Grail, boosting Icahn's case, STAT
  • Indiana governor signs ban on gender-affirming health care, Associated Press
  • Cancer drug shortages have plagued the U.S. for years. Can they be fixed?, STAT

Thanks for reading! More next week,


Enjoying D.C. Diagnosis? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments